Effect of beinaglutide combined with metformin versus aspart 30 with metformin on metabolic profiles and antidrug antibodies in patients with type 2 diabetes: a randomized clinical trial

Effect of beinaglutide combined with metformin versus aspart 30 with metformin on metabolic profiles and antidrug antibodies in patients with type 2 diabetes: a randomized clinical trial

ObjectiveThis prospective study aimed to evaluate the effect of beinaglutide combined with metformin versus aspart 30 with metformin on metabolic profiles and antidrug antibodies (ADAs) in patients with type 2 diabetes (T2D).MethodsA total of 134 eligible participants were randomly assigned to the t...

Full description

Bibliographic Details
Main Authors:	Chen-Yu Han, Jia-Ping Lu, Xiao-Mei Ye, Hai-Ying Jin, Wei-Wei Xu, Ping Wang, Min Zhang
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2023-12-01
Series:	Frontiers in Endocrinology
Subjects:	type 2 diabetes beinaglutide anti-drug antibodies non-fasting triglyceride cardiovascular disease
Online Access:	https://www.frontiersin.org/articles/10.3389/fendo.2023.1267503/full

Similar Items

Short-term effect of beinaglutide combined with metformin versus metformin alone on weight loss and metabolic profiles in obese patients with polycystic ovary syndrome: a pilot randomized trial
by: Qing Wen, et al.
Published: (2023-06-01)

The efficacy and safety of beinaglutide alone or in combination with insulin glargine in Chinese patients with type 2 diabetes mellitus who are inadequately controlled with oral antihyperglycemic therapy: A multicenter, open‐label, randomized trial
by: Xiangyang Liu, et al.
Published: (2024-02-01)

Beinaglutide showed significant weight‐loss benefit and effective glycaemic control for the treatment of type 2 diabetes in a real‐world setting: a 3‐month, multicentre, observational, retrospective, open‐label study
by: Y. L. Zhang, et al.
Published: (2019-08-01)

A Novel Multiphase Modified Ketogenic Diet: An Effective and Safe Tool for Weight Loss in Chinese Obese Patients
by: Wu W, et al.
Published: (2022-08-01)

Correlation between HLA haplotypes and the development of antidrug antibodies in a cohort of patients with rheumatic diseases
by: Benucci M, et al.
Published: (2018-01-01)

Non-fasting triglyceride levels in the Korean population with and without ischemic heart disease and cerebrovascular disease
by: Seo Young Lee, et al.
Published: (2019-03-01)

Fasting, non-fasting and postprandial triglycerides for screening cardiometabolic risk
by: Bryant H. Keirns, et al.
Published: (2021-01-01)

A machine learning approach for identifying variables associated with risk of developing neutralizing antidrug antibodies to factor VIII
by: Atul Rawal, et al.
Published: (2023-06-01)

Assessment of QRISK3 Score in Normoglycaemic, Prediabetic and Diabetic Subjects: An Observational Study
by: Aayushee Rao, et al.
Published: (2023-07-01)

Impact of self-reported fasting duration on lipid profile variability, cardiovascular risk stratification and metabolic syndrome diagnosis
by: Carolina Castro Porto Silva Janovsky, et al.
Published: (2018-04-01)

Efficacy and safety of combination of empagliflozin and metformin with combination of sitagliptin and metformin during Ramadan: an observational study
by: Ibrar Ahmed, et al.
Published: (2022-10-01)

Metformin: a review of its potential indications
by: Wang YW, et al.
Published: (2017-08-01)

Myoinositol and Metformin versus Only Metformin in the Management of Gestational Diabetes Mellitus: A Randomised Open-label Clinical Trial
by: Palash Mazumder, et al.
Published: (2023-04-01)

Antibody against apolipoprotein-A1, non-alcoholic fatty liver disease and cardiovascular risk: a translational study
by: Sabrina Pagano, et al.
Published: (2023-10-01)

Cardiovascular Effects of Metformin
by: B. T. Kurmanbekova, et al.
Published: (2022-03-01)

Relationship Between Non-fasting Triglycerides and Cardiovascular Disease Mortality in a 20-year Follow-up Study of a Japanese General Population: NIPPON DATA90
by: Aya Hirata, et al.
Published: (2022-07-01)

Anti-aging properties of metformin
by: Anna Małgorzata Łopuszyńska, et al.
Published: (2021-09-01)

Postprandial Triglyceride Is Associated with Fasting Triglyceride and HOMA-IR in Korean Subjects with Type 2 Diabetes
by: Seo Hee Lee, et al.
Published: (2011-08-01)

Effects of feed deprivation on physical and blood parameters of horses
by: Paula Alessandra Di Filippo, et al.
Published: (2021-07-01)

Association between Serum Leptin Levels in Obesity and Type 2 Diabetes Mellitus
by: Raviraj Gawali, et al.
Published: (2019-10-01)

Metformin Intervention—A Panacea for Cancer Treatment?
by: Angelika Buczyńska, et al.
Published: (2022-03-01)

Observational Study of Lipid Profile and C-Reactive Protein after a Seven-Day Fast
by: Valeria Galetti, et al.
Published: (2021-01-01)

Metformin ameliorates insulitis in STZ-induced diabetic mice
by: Guo-Jun Jiang, et al.
Published: (2017-04-01)

Metformin in non-diabetic hyperglycaemia: the GLINT feasibility RCT
by: Simon J Griffin, et al.
Published: (2018-04-01)

Gastrointestinal Mechanisms Underlying the Cardiovascular Effect of Metformin
by: Malcolm J. Borg, et al.
Published: (2020-11-01)

Metformin Protects Cardiovascular Health in People With Diabetes
by: Chong Chen, et al.
Published: (2022-07-01)

Cardiovascular effects of metformin: focus on adipose tissue metabolism
by: Olga V. Gruzdeva, et al.
Published: (2022-09-01)

Anti-ENO1 antibody combined with metformin against tumor resistance: a novel antibody-based platform
by: Xiong Shu, et al.
Published: (2024-03-01)

Significance of Metformin Use in Diabetic Kidney Disease
by: Daiji Kawanami, et al.
Published: (2020-06-01)

From Diabetes to Atherosclerosis: Potential of Metformin for Management of Cardiovascular Disease
by: Anastasia V. Poznyak, et al.
Published: (2022-08-01)

Higher fasting triglyceride predicts higher risks of diabetes mortality in US adults
by: Yutang Wang
Published: (2021-12-01)

Metformin: A Reflection on My Journey as Antidiabetic Drug
by: Gurudas Khilnani
Published: (2023-06-01)

Relationship between autoimmune thyroid antibodies and anti-nuclear antibodies in general patients
by: Yi Ruan, et al.
Published: (2024-03-01)

Epitope mapping of anti-drug antibodies to a clinical candidate bispecific antibody
by: Arthur J. Schick, et al.
Published: (2022-12-01)

Metformin and kidney protection; a letter to editor on recent findings
by: Sahar Koushki, et al.
Published: (2019-01-01)

Patient Selection for Pemafibrate Therapy to Prevent Adverse Cardiovascular Events
by: Toshihide Izumida, et al.
Published: (2022-12-01)

Impaired High-density Lipoprotein Antioxidant Activity and Serum Paraoxonase-1 Activity in Type II Diabetic Patients
by: Raveenan Mingpakanee, et al.
Published: (2019-05-01)

Investigating the Status of Antiphospholipid Antibodies in Patients with Mild COVID-19
by: Farshid Mohammadi, et al.
Published: (2023-12-01)

Effects of Metformin on Ischemia/Reperfusion Injury: New Evidence and Mechanisms
by: Estefanie Osorio-Llanes, et al.
Published: (2023-08-01)

Risk of antidepressant initiation among users of cardiovascular agents and metformin.
by: Ivana Bojanić, et al.
Published: (2023-04-01)